Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 113 | 2024 | 6951 | 10.290 |
Why?
|
Proviruses | 24 | 2024 | 319 | 6.030 |
Why?
|
HIV Infections | 129 | 2024 | 17542 | 5.930 |
Why?
|
CD4-Positive T-Lymphocytes | 57 | 2024 | 4405 | 5.390 |
Why?
|
Virus Latency | 20 | 2024 | 359 | 5.010 |
Why?
|
Viral Load | 40 | 2024 | 3385 | 2.640 |
Why?
|
HIV Seropositivity | 9 | 2023 | 963 | 2.420 |
Why?
|
CD8-Positive T-Lymphocytes | 42 | 2022 | 4648 | 2.240 |
Why?
|
HIV Long-Term Survivors | 9 | 2018 | 140 | 2.160 |
Why?
|
Anti-Retroviral Agents | 20 | 2024 | 1787 | 2.030 |
Why?
|
DNA, Viral | 16 | 2022 | 2201 | 1.900 |
Why?
|
Disease Reservoirs | 8 | 2020 | 123 | 1.550 |
Why?
|
T-Lymphocyte Subsets | 8 | 2022 | 1814 | 1.250 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2014 | 376 | 1.110 |
Why?
|
Anti-HIV Agents | 21 | 2024 | 4567 | 1.100 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2020 | 976 | 1.080 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2024 | 777 | 1.050 |
Why?
|
Virus Replication | 17 | 2024 | 2457 | 1.050 |
Why?
|
Genome, Viral | 4 | 2020 | 673 | 0.980 |
Why?
|
Viremia | 15 | 2024 | 726 | 0.980 |
Why?
|
Virus Integration | 5 | 2024 | 307 | 0.940 |
Why?
|
Receptors, HIV | 2 | 2017 | 159 | 0.920 |
Why?
|
Interferon-alpha | 5 | 2024 | 909 | 0.920 |
Why?
|
Immunity, Innate | 9 | 2024 | 3076 | 0.840 |
Why?
|
Antiretroviral Therapy, Highly Active | 16 | 2019 | 1902 | 0.820 |
Why?
|
Dendritic Cells | 18 | 2023 | 2745 | 0.780 |
Why?
|
Th1 Cells | 3 | 2020 | 1040 | 0.770 |
Why?
|
T-Lymphocytes, Cytotoxic | 15 | 2022 | 1801 | 0.720 |
Why?
|
Viral Tropism | 2 | 2017 | 102 | 0.670 |
Why?
|
Immunologic Memory | 5 | 2023 | 1377 | 0.630 |
Why?
|
AIDS Vaccines | 8 | 2024 | 900 | 0.610 |
Why?
|
Phylogeny | 5 | 2022 | 2840 | 0.600 |
Why?
|
Acquired Immunodeficiency Syndrome | 9 | 2009 | 2204 | 0.590 |
Why?
|
Histocompatibility Antigens Class I | 10 | 2022 | 1362 | 0.550 |
Why?
|
Killer Cells, Natural | 10 | 2023 | 2209 | 0.530 |
Why?
|
Hydroxamic Acids | 3 | 2016 | 483 | 0.520 |
Why?
|
HIV | 6 | 2021 | 1591 | 0.520 |
Why?
|
Hepatitis C | 4 | 2018 | 1594 | 0.520 |
Why?
|
Humans | 157 | 2024 | 767040 | 0.510 |
Why?
|
Base Sequence | 8 | 2022 | 12414 | 0.500 |
Why?
|
Evolution, Molecular | 5 | 2019 | 1893 | 0.490 |
Why?
|
Cyclin-Dependent Kinase 2 | 2 | 2014 | 185 | 0.470 |
Why?
|
Ribavirin | 3 | 2018 | 395 | 0.460 |
Why?
|
HIV Antibodies | 5 | 2023 | 1340 | 0.460 |
Why?
|
Receptors, Immunologic | 6 | 2014 | 1418 | 0.460 |
Why?
|
Telomerase | 2 | 2010 | 751 | 0.460 |
Why?
|
Leukocytes, Mononuclear | 9 | 2024 | 1854 | 0.450 |
Why?
|
Lymphoid Progenitor Cells | 1 | 2014 | 21 | 0.450 |
Why?
|
Lymph Nodes | 4 | 2023 | 3468 | 0.440 |
Why?
|
HIV Reverse Transcriptase | 1 | 2014 | 214 | 0.430 |
Why?
|
RNA, Viral | 11 | 2024 | 2867 | 0.430 |
Why?
|
CD4 Lymphocyte Count | 11 | 2024 | 2586 | 0.410 |
Why?
|
Receptors, CXCR4 | 1 | 2017 | 729 | 0.410 |
Why?
|
Cell Polarity | 1 | 2015 | 637 | 0.390 |
Why?
|
Monocytes | 5 | 2020 | 2598 | 0.390 |
Why?
|
Epitopes, T-Lymphocyte | 11 | 2021 | 827 | 0.390 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 3 | 2023 | 545 | 0.390 |
Why?
|
Receptors, CCR5 | 3 | 2021 | 491 | 0.380 |
Why?
|
Telomere-Binding Proteins | 1 | 2012 | 122 | 0.370 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1907 | 0.370 |
Why?
|
Antigen Presentation | 7 | 2012 | 1250 | 0.360 |
Why?
|
Myeloid Cells | 3 | 2021 | 837 | 0.360 |
Why?
|
Indoles | 3 | 2016 | 1836 | 0.360 |
Why?
|
Botswana | 6 | 2023 | 1056 | 0.360 |
Why?
|
Ritonavir | 2 | 2003 | 331 | 0.350 |
Why?
|
HLA-B Antigens | 5 | 2016 | 330 | 0.350 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2020 | 620 | 0.340 |
Why?
|
HIV Protease Inhibitors | 2 | 2003 | 430 | 0.340 |
Why?
|
Daptomycin | 1 | 2009 | 71 | 0.320 |
Why?
|
Heterochromatin | 2 | 2023 | 294 | 0.320 |
Why?
|
Stem Cells | 4 | 2019 | 3535 | 0.320 |
Why?
|
Th17 Cells | 1 | 2015 | 790 | 0.310 |
Why?
|
Flow Cytometry | 11 | 2017 | 5891 | 0.310 |
Why?
|
Antiviral Agents | 6 | 2023 | 3070 | 0.310 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 705 | 0.310 |
Why?
|
Transcription, Genetic | 2 | 2022 | 7611 | 0.310 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2014 | 923 | 0.300 |
Why?
|
Glycopeptides | 1 | 2009 | 225 | 0.300 |
Why?
|
Infectious Disease Transmission, Vertical | 4 | 2024 | 1354 | 0.300 |
Why?
|
HLA-A3 Antigen | 2 | 2006 | 34 | 0.280 |
Why?
|
Phenotype | 2 | 2023 | 16718 | 0.280 |
Why?
|
Chromosomes, Human | 2 | 2019 | 437 | 0.280 |
Why?
|
Adult | 55 | 2024 | 223317 | 0.280 |
Why?
|
Toll-Like Receptor 9 | 2 | 2019 | 197 | 0.280 |
Why?
|
Simian immunodeficiency virus | 3 | 2023 | 814 | 0.270 |
Why?
|
Virus Activation | 3 | 2020 | 322 | 0.270 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2006 | 70 | 0.260 |
Why?
|
Infant, Newborn | 9 | 2024 | 26396 | 0.260 |
Why?
|
Antibodies, Neutralizing | 3 | 2023 | 2011 | 0.260 |
Why?
|
Endocarditis, Bacterial | 1 | 2009 | 436 | 0.250 |
Why?
|
Middle Aged | 47 | 2024 | 223233 | 0.250 |
Why?
|
Female | 61 | 2024 | 396660 | 0.240 |
Why?
|
Male | 58 | 2024 | 364203 | 0.240 |
Why?
|
Cell Survival | 6 | 2023 | 5750 | 0.240 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5716 | 0.240 |
Why?
|
Cell Proliferation | 8 | 2024 | 10455 | 0.240 |
Why?
|
Genes, nef | 1 | 2004 | 52 | 0.230 |
Why?
|
Down-Regulation | 1 | 2012 | 2931 | 0.230 |
Why?
|
Hemophilia B | 1 | 2005 | 83 | 0.230 |
Why?
|
Cytotoxicity, Immunologic | 3 | 2014 | 1352 | 0.230 |
Why?
|
Immunity, Cellular | 5 | 2015 | 1560 | 0.220 |
Why?
|
Leukocytes | 1 | 2011 | 2034 | 0.220 |
Why?
|
Receptors, Chemokine | 2 | 2007 | 652 | 0.220 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 812 | 0.210 |
Why?
|
Interferon-gamma | 7 | 2015 | 3154 | 0.210 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 3667 | 0.210 |
Why?
|
Receptors, Interleukin-21 | 1 | 2023 | 32 | 0.210 |
Why?
|
Mozambique | 1 | 2022 | 55 | 0.210 |
Why?
|
Liver Failure | 1 | 2005 | 252 | 0.210 |
Why?
|
Interleukins | 3 | 2017 | 796 | 0.210 |
Why?
|
Membrane Glycoproteins | 6 | 2014 | 3702 | 0.210 |
Why?
|
Alleles | 7 | 2022 | 6893 | 0.210 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 149 | 0.200 |
Why?
|
Ionomycin | 1 | 2022 | 109 | 0.200 |
Why?
|
Drug Resistance, Bacterial | 1 | 2009 | 1063 | 0.200 |
Why?
|
Sequence Analysis, DNA | 3 | 2022 | 4780 | 0.200 |
Why?
|
Indinavir | 1 | 2002 | 73 | 0.200 |
Why?
|
Sarcoma, Kaposi | 1 | 2005 | 376 | 0.200 |
Why?
|
B-Lymphocyte Subsets | 1 | 2023 | 240 | 0.190 |
Why?
|
Gene Products, gag | 4 | 2007 | 318 | 0.190 |
Why?
|
Hemophilia A | 1 | 2005 | 359 | 0.190 |
Why?
|
Delusions | 1 | 2024 | 300 | 0.190 |
Why?
|
Molecular Sequence Data | 13 | 2014 | 17608 | 0.190 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2005 | 678 | 0.190 |
Why?
|
Cyclin-Dependent Kinase 9 | 2 | 2011 | 68 | 0.190 |
Why?
|
Antigens, CD | 6 | 2015 | 4032 | 0.180 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2022 | 826 | 0.180 |
Why?
|
Basal Ganglia | 1 | 2023 | 549 | 0.180 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2020 | 296 | 0.180 |
Why?
|
Staphylococcal Infections | 1 | 2009 | 1396 | 0.180 |
Why?
|
Species Specificity | 4 | 2014 | 2412 | 0.180 |
Why?
|
Genes, MHC Class I | 4 | 2010 | 236 | 0.180 |
Why?
|
Lymphocyte Activation | 5 | 2020 | 5499 | 0.170 |
Why?
|
Infant | 9 | 2024 | 36485 | 0.170 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 2000 | 141 | 0.170 |
Why?
|
Up-Regulation | 4 | 2014 | 4143 | 0.170 |
Why?
|
HLA Antigens | 3 | 2011 | 1334 | 0.170 |
Why?
|
Integrins | 2 | 2024 | 840 | 0.170 |
Why?
|
Lectins, C-Type | 1 | 2003 | 591 | 0.170 |
Why?
|
Gene Expression Profiling | 5 | 2020 | 9532 | 0.160 |
Why?
|
Acute Disease | 7 | 2019 | 7236 | 0.160 |
Why?
|
Cells, Cultured | 8 | 2020 | 18989 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2000 | 225 | 0.160 |
Why?
|
Amino Acid Sequence | 13 | 2014 | 13411 | 0.160 |
Why?
|
Lymphocyte Subsets | 2 | 2014 | 313 | 0.160 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 166 | 0.160 |
Why?
|
Pyrimidinones | 2 | 2019 | 385 | 0.150 |
Why?
|
Doxorubicin | 1 | 2005 | 2229 | 0.150 |
Why?
|
Helicobacter pylori | 1 | 2002 | 380 | 0.150 |
Why?
|
Clone Cells | 1 | 2022 | 1669 | 0.150 |
Why?
|
Helicobacter Infections | 1 | 2002 | 390 | 0.150 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2002 | 663 | 0.150 |
Why?
|
Antigens, CD34 | 1 | 2000 | 655 | 0.150 |
Why?
|
South Africa | 2 | 2024 | 1873 | 0.150 |
Why?
|
Germinal Center | 1 | 2020 | 379 | 0.140 |
Why?
|
Hepatitis C, Chronic | 2 | 2002 | 1032 | 0.140 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2020 | 4349 | 0.140 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4114 | 0.140 |
Why?
|
Cell Adhesion Molecules | 1 | 2003 | 1612 | 0.140 |
Why?
|
Interferons | 2 | 2022 | 716 | 0.130 |
Why?
|
Fatty Liver | 1 | 2003 | 811 | 0.130 |
Why?
|
Biological Evolution | 1 | 2022 | 1075 | 0.130 |
Why?
|
Gene Silencing | 2 | 2020 | 1505 | 0.130 |
Why?
|
Gene Products, nef | 2 | 2006 | 102 | 0.120 |
Why?
|
Immunocompromised Host | 1 | 2020 | 862 | 0.120 |
Why?
|
Vaccines, Subunit | 2 | 2014 | 159 | 0.120 |
Why?
|
Aged | 16 | 2022 | 171319 | 0.120 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4855 | 0.120 |
Why?
|
Young Adult | 11 | 2020 | 59980 | 0.120 |
Why?
|
DNA | 2 | 2019 | 7210 | 0.120 |
Why?
|
Reverse Transcription | 1 | 2014 | 48 | 0.120 |
Why?
|
T-Lymphocytes | 3 | 2017 | 10254 | 0.110 |
Why?
|
Caspase 8 | 1 | 2014 | 198 | 0.110 |
Why?
|
HIV Antigens | 2 | 2005 | 328 | 0.110 |
Why?
|
Cohort Studies | 14 | 2018 | 41718 | 0.110 |
Why?
|
Metabolic Networks and Pathways | 1 | 2018 | 800 | 0.110 |
Why?
|
Immunodominant Epitopes | 5 | 2006 | 244 | 0.110 |
Why?
|
Cell Count | 2 | 2015 | 1825 | 0.110 |
Why?
|
Enzyme Stability | 1 | 2014 | 218 | 0.110 |
Why?
|
Depsipeptides | 1 | 2014 | 95 | 0.110 |
Why?
|
Host-Pathogen Interactions | 3 | 2021 | 1466 | 0.110 |
Why?
|
Toll-Like Receptor 1 | 1 | 2013 | 48 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2007 | 2568 | 0.110 |
Why?
|
Phosphopeptides | 1 | 2014 | 240 | 0.110 |
Why?
|
Receptors, Cell Surface | 1 | 2003 | 2815 | 0.110 |
Why?
|
Lipopeptides | 1 | 2013 | 71 | 0.110 |
Why?
|
Case-Control Studies | 6 | 2024 | 22254 | 0.110 |
Why?
|
Disease Progression | 8 | 2017 | 13646 | 0.100 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 505 | 0.100 |
Why?
|
Polyethylene Glycols | 1 | 2018 | 1188 | 0.100 |
Why?
|
HLA-DR Antigens | 2 | 2012 | 609 | 0.100 |
Why?
|
Liver | 2 | 2005 | 7578 | 0.100 |
Why?
|
Polymerase Chain Reaction | 6 | 2020 | 6067 | 0.100 |
Why?
|
Rectum | 1 | 2017 | 898 | 0.100 |
Why?
|
Genotype | 4 | 2021 | 13035 | 0.100 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 120 | 0.100 |
Why?
|
Time Factors | 6 | 2019 | 40154 | 0.090 |
Why?
|
Drug Therapy, Combination | 5 | 2006 | 6310 | 0.090 |
Why?
|
Toll-Like Receptor 2 | 1 | 2013 | 348 | 0.090 |
Why?
|
Epigenesis, Genetic | 2 | 2022 | 3828 | 0.090 |
Why?
|
RNA, Small Interfering | 4 | 2015 | 3427 | 0.090 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2014 | 1531 | 0.090 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7469 | 0.090 |
Why?
|
Nevirapine | 2 | 2023 | 273 | 0.090 |
Why?
|
Histone Deacetylases | 1 | 2015 | 712 | 0.090 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 381 | 0.090 |
Why?
|
RNA, Messenger | 4 | 2011 | 12793 | 0.090 |
Why?
|
DNA Primers | 3 | 2011 | 2827 | 0.090 |
Why?
|
Prospective Studies | 5 | 2024 | 54886 | 0.090 |
Why?
|
Genetic Variation | 4 | 2019 | 6611 | 0.090 |
Why?
|
Receptors, CXCR5 | 2 | 2023 | 88 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1592 | 0.080 |
Why?
|
Th2 Cells | 1 | 2015 | 1077 | 0.080 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2040 | 0.080 |
Why?
|
Chromatin | 1 | 2022 | 2980 | 0.080 |
Why?
|
Cytokines | 5 | 2017 | 7446 | 0.080 |
Why?
|
HLA-A Antigens | 2 | 2006 | 223 | 0.080 |
Why?
|
Immunophenotyping | 3 | 2014 | 1864 | 0.080 |
Why?
|
Early Diagnosis | 1 | 2013 | 1188 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2850 | 0.070 |
Why?
|
Child | 7 | 2024 | 80771 | 0.070 |
Why?
|
Apoptosis | 2 | 2018 | 9513 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2013 | 560 | 0.070 |
Why?
|
HLA-B27 Antigen | 1 | 2007 | 66 | 0.070 |
Why?
|
Oxazines | 2 | 2020 | 358 | 0.070 |
Why?
|
Hematopoietic Stem Cells | 1 | 2000 | 3408 | 0.070 |
Why?
|
Inflammation | 2 | 2024 | 10869 | 0.070 |
Why?
|
International Cooperation | 1 | 2014 | 1434 | 0.070 |
Why?
|
RNA Polymerase II | 1 | 2011 | 549 | 0.070 |
Why?
|
Withholding Treatment | 2 | 2024 | 619 | 0.070 |
Why?
|
Mutation | 7 | 2021 | 30211 | 0.070 |
Why?
|
Cluster Analysis | 1 | 2014 | 2721 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4572 | 0.070 |
Why?
|
Phosphorylation | 2 | 2014 | 8310 | 0.070 |
Why?
|
Adjuvants, Immunologic | 1 | 2012 | 998 | 0.070 |
Why?
|
Drug Resistance, Viral | 2 | 2021 | 868 | 0.070 |
Why?
|
Cell Degranulation | 1 | 2007 | 276 | 0.060 |
Why?
|
B-Lymphocytes | 4 | 2020 | 4787 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2017 | 3043 | 0.060 |
Why?
|
Diseases in Twins | 1 | 2007 | 447 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2019 | 14766 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3792 | 0.060 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 2005 | 151 | 0.060 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 207 | 0.060 |
Why?
|
Pyridones | 2 | 2020 | 819 | 0.060 |
Why?
|
Child, Preschool | 6 | 2024 | 42606 | 0.060 |
Why?
|
Ligands | 2 | 2008 | 3273 | 0.060 |
Why?
|
Viral Structural Proteins | 1 | 2004 | 93 | 0.060 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2007 | 661 | 0.060 |
Why?
|
Gene Expression Regulation | 4 | 2020 | 11923 | 0.060 |
Why?
|
Cross Reactions | 1 | 2006 | 828 | 0.060 |
Why?
|
Lamivudine | 2 | 2021 | 367 | 0.060 |
Why?
|
Signal Transduction | 4 | 2021 | 23621 | 0.060 |
Why?
|
Interleukin-12 | 2 | 2020 | 577 | 0.050 |
Why?
|
Immunoglobulin D | 1 | 2023 | 55 | 0.050 |
Why?
|
Amino Acid Substitution | 2 | 2006 | 1743 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2715 | 0.050 |
Why?
|
Zidovudine | 2 | 2021 | 625 | 0.050 |
Why?
|
Interleukin-2 | 2 | 2014 | 1894 | 0.050 |
Why?
|
Genes, Viral | 1 | 2004 | 654 | 0.050 |
Why?
|
HIV-2 | 1 | 2023 | 156 | 0.050 |
Why?
|
Hepatomegaly | 1 | 2003 | 84 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2008 | 1150 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 186 | 0.050 |
Why?
|
RNA Interference | 1 | 2011 | 2829 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 2428 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2012 | 2322 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3112 | 0.050 |
Why?
|
Receptors, CCR1 | 1 | 2002 | 30 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7587 | 0.050 |
Why?
|
Lung Diseases, Fungal | 1 | 2003 | 123 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3234 | 0.050 |
Why?
|
Chemokine CCL3 | 1 | 2002 | 85 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2002 | 114 | 0.050 |
Why?
|
Chemokine CCL4 | 1 | 2002 | 127 | 0.050 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2002 | 122 | 0.050 |
Why?
|
Receptors, CCR4 | 1 | 2002 | 77 | 0.050 |
Why?
|
Tandem Repeat Sequences | 1 | 2003 | 183 | 0.050 |
Why?
|
Mitochondria, Liver | 1 | 2003 | 190 | 0.050 |
Why?
|
Telomere | 1 | 2008 | 943 | 0.050 |
Why?
|
Transaminases | 1 | 2003 | 198 | 0.050 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 213 | 0.050 |
Why?
|
Ileum | 1 | 2024 | 558 | 0.050 |
Why?
|
Receptors, CXCR3 | 2 | 2017 | 240 | 0.050 |
Why?
|
Caspase 3 | 1 | 2004 | 730 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2017 | 26325 | 0.050 |
Why?
|
Chemokine CCL5 | 1 | 2002 | 214 | 0.050 |
Why?
|
Macaca mulatta | 2 | 2019 | 2345 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3700 | 0.050 |
Why?
|
Liposomes | 1 | 2005 | 787 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6001 | 0.050 |
Why?
|
Argentina | 1 | 2021 | 249 | 0.050 |
Why?
|
Caspases | 1 | 2004 | 881 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9360 | 0.040 |
Why?
|
HIV Core Protein p24 | 2 | 2014 | 245 | 0.040 |
Why?
|
Animals | 7 | 2023 | 168965 | 0.040 |
Why?
|
Nucleotidyltransferases | 1 | 2022 | 242 | 0.040 |
Why?
|
Linear Models | 3 | 2016 | 5875 | 0.040 |
Why?
|
DNA, Satellite | 1 | 2020 | 67 | 0.040 |
Why?
|
Epitopes | 4 | 2010 | 2526 | 0.040 |
Why?
|
Integrin alpha4beta1 | 1 | 2000 | 119 | 0.040 |
Why?
|
STAT4 Transcription Factor | 1 | 2020 | 94 | 0.040 |
Why?
|
Substrate Specificity | 1 | 2004 | 1750 | 0.040 |
Why?
|
Transcription Initiation Site | 1 | 2020 | 190 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 190 | 0.040 |
Why?
|
Mycoses | 1 | 2003 | 386 | 0.040 |
Why?
|
Drug Design | 1 | 2005 | 1045 | 0.040 |
Why?
|
Nausea | 1 | 2003 | 682 | 0.040 |
Why?
|
Culicidae | 1 | 2020 | 111 | 0.040 |
Why?
|
Pregnancy | 4 | 2024 | 30238 | 0.040 |
Why?
|
Centromere | 1 | 2020 | 214 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2018 | 6507 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 18063 | 0.040 |
Why?
|
CREB-Binding Protein | 1 | 2019 | 147 | 0.040 |
Why?
|
Germany | 1 | 2002 | 882 | 0.040 |
Why?
|
Vomiting | 1 | 2003 | 655 | 0.040 |
Why?
|
Alkynes | 1 | 2020 | 326 | 0.040 |
Why?
|
Piperazines | 2 | 2020 | 2548 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2020 | 350 | 0.040 |
Why?
|
Remission Induction | 1 | 2005 | 2408 | 0.040 |
Why?
|
Surface Properties | 1 | 2002 | 1154 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 3114 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39317 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 501 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 220 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2020 | 436 | 0.040 |
Why?
|
Treatment Outcome | 6 | 2019 | 65295 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 3804 | 0.040 |
Why?
|
Defective Viruses | 1 | 2018 | 89 | 0.040 |
Why?
|
Benzoxazines | 1 | 2020 | 320 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2000 | 692 | 0.040 |
Why?
|
Algorithms | 2 | 2020 | 14098 | 0.040 |
Why?
|
Glycosylation | 1 | 2020 | 1099 | 0.040 |
Why?
|
Endothelium | 1 | 2000 | 768 | 0.040 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 2017 | 27 | 0.040 |
Why?
|
Lactic Acid | 1 | 2003 | 1139 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2012 | 12451 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2000 | 631 | 0.040 |
Why?
|
Cercocebus atys | 1 | 2017 | 12 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10393 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 16036 | 0.030 |
Why?
|
Viral Proteins | 1 | 2004 | 1801 | 0.030 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 117 | 0.030 |
Why?
|
Glycolysis | 1 | 2021 | 836 | 0.030 |
Why?
|
Spain | 1 | 2018 | 483 | 0.030 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2017 | 85 | 0.030 |
Why?
|
Peptides | 2 | 2010 | 4348 | 0.030 |
Why?
|
Leukemia, T-Cell | 1 | 2017 | 102 | 0.030 |
Why?
|
Magnesium | 1 | 2000 | 815 | 0.030 |
Why?
|
Brain | 1 | 2023 | 27163 | 0.030 |
Why?
|
Receptors, CCR6 | 1 | 2017 | 73 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2000 | 1337 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2003 | 1069 | 0.030 |
Why?
|
Blotting, Western | 2 | 2015 | 5022 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2013 | 81659 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2078 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2016 | 126 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1836 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2018 | 751 | 0.030 |
Why?
|
Ubiquitins | 1 | 2017 | 365 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 620 | 0.030 |
Why?
|
Cyclin A | 1 | 2014 | 59 | 0.030 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2015 | 511 | 0.030 |
Why?
|
Outpatients | 1 | 2003 | 1600 | 0.030 |
Why?
|
Cell Line | 2 | 2020 | 15567 | 0.030 |
Why?
|
beta Catenin | 1 | 2019 | 1048 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3227 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 788 | 0.030 |
Why?
|
Spleen | 1 | 2020 | 2292 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2017 | 828 | 0.030 |
Why?
|
Gene Products, tat | 1 | 2014 | 111 | 0.030 |
Why?
|
Epitope Mapping | 2 | 2005 | 301 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2086 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2000 | 3093 | 0.030 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2014 | 146 | 0.030 |
Why?
|
Chronic Disease | 2 | 2005 | 9362 | 0.030 |
Why?
|
Adolescent | 3 | 2013 | 89046 | 0.030 |
Why?
|
Bystander Effect | 1 | 2013 | 89 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2017 | 1076 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4247 | 0.030 |
Why?
|
Medication Adherence | 1 | 2024 | 2191 | 0.030 |
Why?
|
Calibration | 1 | 2014 | 817 | 0.020 |
Why?
|
Vaccines, Synthetic | 1 | 2014 | 621 | 0.020 |
Why?
|
Hepacivirus | 1 | 2018 | 1342 | 0.020 |
Why?
|
Biopsy | 1 | 2003 | 6777 | 0.020 |
Why?
|
Survival Rate | 1 | 2005 | 12823 | 0.020 |
Why?
|
Proteomics | 1 | 2024 | 3913 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2019 | 11657 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2972 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1604 | 0.020 |
Why?
|
Necrosis | 1 | 2014 | 1614 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1621 | 0.020 |
Why?
|
Mothers | 1 | 2020 | 2209 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2020 | 2979 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1596 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8504 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2014 | 3587 | 0.020 |
Why?
|
Solubility | 1 | 2010 | 1078 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8890 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1559 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20169 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2183 | 0.020 |
Why?
|
Protein Binding | 1 | 2000 | 9327 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3738 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2005 | 15925 | 0.020 |
Why?
|
Comorbidity | 1 | 2002 | 10582 | 0.020 |
Why?
|
Stavudine | 1 | 2006 | 85 | 0.020 |
Why?
|
Antigenic Variation | 1 | 2006 | 117 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2538 | 0.020 |
Why?
|
Kinetics | 1 | 2014 | 6287 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2013 | 1791 | 0.020 |
Why?
|
Twins, Monozygotic | 1 | 2007 | 471 | 0.020 |
Why?
|
Homeostasis | 1 | 2017 | 3345 | 0.020 |
Why?
|
Gene Products, vpr | 1 | 2005 | 33 | 0.020 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 36 | 0.020 |
Why?
|
Risk Factors | 2 | 2024 | 74886 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4522 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2005 | 363 | 0.020 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2004 | 25 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14672 | 0.010 |
Why?
|
Cell Movement | 1 | 2017 | 5203 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2006 | 717 | 0.010 |
Why?
|
Mass Screening | 1 | 2020 | 5456 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2255 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 59548 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8048 | 0.010 |
Why?
|
Aspergillus flavus | 1 | 2003 | 13 | 0.010 |
Why?
|
Aspergillus niger | 1 | 2003 | 18 | 0.010 |
Why?
|
Scedosporium | 1 | 2003 | 10 | 0.010 |
Why?
|
Lung | 1 | 2022 | 10076 | 0.010 |
Why?
|
Fusarium | 1 | 2003 | 50 | 0.010 |
Why?
|
Aspergillus | 1 | 2003 | 94 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2005 | 793 | 0.010 |
Why?
|
Thermodynamics | 1 | 2004 | 581 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2014 | 5141 | 0.010 |
Why?
|
Aspergillus fumigatus | 1 | 2003 | 158 | 0.010 |
Why?
|
Genomics | 1 | 2018 | 5924 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2005 | 1160 | 0.010 |
Why?
|
Vaccination | 1 | 2014 | 3434 | 0.010 |
Why?
|
Aspergillosis | 1 | 2003 | 241 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2003 | 757 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8736 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2004 | 1494 | 0.010 |
Why?
|
Selection, Genetic | 1 | 2004 | 877 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 20741 | 0.010 |
Why?
|
Autopsy | 1 | 2003 | 1011 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 13485 | 0.010 |
Why?
|
China | 1 | 2004 | 2394 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 4918 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9245 | 0.010 |
Why?
|
Liver Diseases | 1 | 2002 | 1304 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12536 | 0.010 |
Why?
|
Pilot Projects | 1 | 2002 | 8732 | 0.000 |
Why?
|